SCHEMBL2861463

SCHEMBL2861463

COCCCOc1ccc2c(c1)[nH]c(=O)c1c(N)n(-c3cc(OC)c(Oc4ccccc4)cc3C)nc12

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PDE2A O00408 3/20 0.35
NR1H4 Q96RI1 1/20 0.33
NTRK1 P04629 2/20 0.33
NTRK2 Q16620 2/20 0.33
NTRK3 Q16288 1/20 0.33
DRD2 P14416 5/20 0.32
DRD4 P21917 4/20 0.32
DRD3 P35462 4/20 0.32
MAOA P21397 1/20 0.32
DYRK1A Q13627 1/20 0.32
SERPINE1 P05121 1/20 0.32
KYAT3 Q6YP21 1/20 0.32
AADAT Q8N5Z0 1/20 0.32
IGF1R P08069 1/20 0.32
FGFR1 P11362 1/20 0.32
BTK Q06187 2/20 0.32
PDE10A Q9Y233 1/20 0.31
ADORA3 P0DMS8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5790922 0.89 GAA (0.37) PDE2AKYAT3AADATFGFR1BTK
SCHEMBL2867315 0.89 PDGFRB (0.33) PDE2ANTRK1NTRK2KYAT3AADAT
SCHEMBL2868101 0.88 MAOA (0.35) PDE2ADRD2DRD3MAOADYRK1A
SCHEMBL13025340 0.88 SMN1; SMN2 (0.40) DYRK1AKYAT3AADATBTK
SCHEMBL2869051 0.87 TSHR (0.34) NTRK1NTRK2KYAT3AADATIGF1R
SCHEMBL2871110 0.86 MAOA (0.40) PDE2ADRD2MAOADYRK1AFGFR1
SCHEMBL2868573 0.86 ADORA3 (0.39) NTRK1NTRK2KYAT3AADATIGF1R
SCHEMBL2861219 0.86 KYAT3 (0.36) NR1H4NTRK1NTRK2KYAT3AADAT
SCHEMBL2857657 0.85 POLB (0.37) NR1H4NTRK1NTRK2KYAT3AADAT
SCHEMBL2871146 0.84 MAOA (0.36) PDE2ANTRK1NTRK2MAOAIGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
EP-1719771-A1 PYRAZOLOQUINOLONE DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2006-11-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof MAP3K20, MAP4K5, MAP4K3 PDE2A 2228/4885NR1H4 1253/4885NTRK1 381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.